

Index

NOTE: Terms that are defined in the Glossary appear below in *italics*.

- acupuncture / acupuncturists (LAC), 76, 77, 78, 79, 80
adjuvant therapy, 44–45, 46–47, 48–49, 131
adrenal gland, 46
Adriamycin, 49
advocacy, political, 141–142
albumin-bound-paclitaxel (Abraxane), 49, 133
alcohol drinking, 12, 83, 112, 114
alendronate (Fosamax), 117
alopecia, 50, 56–57
Aloxi, 58
alprazolam (Xanax), 114
American Cancer Society, 4
 estimates of deaths by, 5
 free services, 121
 patient services, 61
 publications by, 64, 124; Appendix B; Appendix C
 Reach to Recovery, 59
 support organizations and resources, 79; Appendix B
American Society of Plastic and Reconstructive Surgeons, 37
anastrozole (Arimidex), 13, 28, 46
androgens, 46
angiogenesis, 136
 inhibition, 49, 134–135
antibiotics, 90
antidepressants, 103–104, 113
anti-estrogens, 47–48, 117
aprepitant (Emed), 58
aromatase inhibitors, 13, 28, 46–47, 130
attitude, positive, 22
atypia, 9, 33
Avastin, 135
axillary lymph node dissection, 33–34, 132
- bellergal (including belladonna), 113
benign, 8
benzodiazepines, 114
bevacizumab (Avastin), 51–52
biologic therapy, 44, 51–52, 76, 134
biopsy, 17, 28, 34
bisphosphonates, 46, 52, 117, 135
birth control pills, as risk factor, 9–10
black cohosh (remifemin), 113
blood counts, 92
blood tests, 29
Bloom-Richardson scale, 28
blue dye, 34
body image / changes, 106, 107
Bondronat, 135
bone marrow, 49, 50
bone scans, 29, 92
botanical (herbs) medicines / botanicals, 76, 77, 78
brachytherapy, 41, 132–133
bras, 58–61
breast cancer, 137. *See also* diagnosis; prevention; risk factors; staging; treatment
 benign, 8
 biology, 128–129
 causes of, 11, 129
 development and progression of, 81
 early detection, 5, 65, 96, 130
 early stage, 47, 49, 52, 131, 133, 135, 137
 hereditary / genes, 10, 129
 incidence / frequency, 4
 in Washington state, 4
 in young women, 64
 inflammatory, 27
 in situ, 4
 invasive, 4, 27, 29, 33, 130
 lobular, 26
 localized, 4
 metastatic, 26, 40–41, 46, 47, 49, 51, 97, 133, 134, 135
 mortality, 4, 96
 prognosis, 28
 recurrence, 9, 27, 29, 44, 46, 47, 82, 96–97, 131, 134, 136, 137
 coping with, 97–98
 stages of, 26–28, 41, 65
 survival rates, 5, 64
 survivors / survivorship, 5, 112, 136–137, 141. *See also* cancer, survivors
 vaccines, 136
 in young women, 64–66
Breast Cancer Awareness Month, 140
Breast Cancer Facts and Figures 2005–2006, 5
breast conservation, 29, 32, 33, 34, 132
breast disease, *benign*, 8
breast exam, clinical, 16–17
breast implants, 35
breast reconstruction, 13, 35, 37, 122, 132
 questions to ask your surgeon, 35
breast self-exam (BSE), 16, 17, 64–65, 92
- caffeine use, 112, 114
calcification. *See* microcalcification
calcium, 116
camisoles, postoperative, 59
cancer. *See also* breast cancer
 cell, understanding, 128, 131
 and employment / medical leave, 6
 prevention, 76, 77
 spread, 26–27, 30, 44, 131, 135. *See also* metastasis
 survivors, 76, 77, 78, 79, 93
Cancer and Leukemia Group B (CALGB), 49, 70
Cancer Lifeline, 79
capecitabine (Xeloda), 49
carcinogens, 11, 14
 environmental, 8
carcinoma in situ, 27
caregiving by family and friends, 106, 108
catheters, 53–54
celecoxib (Celebrex), 130
cell, 131–132, 137. *See also* cancer
CellSearch, 132
Centerwatch, 133
chemoprevention, 11, 12–13, 47, 130
chemotherapy, 28, 29, 33, 44, 76, 128. *See also* adjuvant therapy
 bisphosphonates and, 52, 135
 combination, 48
 drugs, 48, 49, 52
 and early menopause, 65
 exercise during, 86
 and hair loss, 56–57, 106
 HER-2 and, 134
 high-dose, 50
 for recurrence, 96
 research, 133–134
 side effects of, 49–50
children, effects of mother's cancer on, 114–105
Chinese medicines, 78, 79. *See also* traditional Chinese medicine
chiropractic therapies, 76
circulating tumor cells (CTCs), 132
clinical trials, 68–73, 132, 133, 137
 of drugs, vitamins, and other supplements, 130
 HER-2, 134
 NIH database of, 133
 patient participation in, 73
 phases, 70–71
 protocol, study / research, 69
 with targeted agents, 134–136
 types of, 68–69
 of vaccines, 136
clodronate (Bonefos), 52, 135
- clonidine, 113
colon cancer, 13
colorectal cancer, 51, 135
communication
 with doctor, 21, 23
 with partner, 107
Community Clinical Oncology Programs (CCEP), 69
complementary and alternative medicine (CAM), 76
 guidelines, 80
 sources for, 78–79
 types of, 77–78
computed tomography (CT), 29
contraception methods during treatment, 65
core needle biopsy, 17
counseling / counselors, 78, 79, 98, 103, 105, 107
 for stress, 114
COX-2 inhibitors, 13, 130
cyclophosphamide (Cytoxan), 49
cysts, 9
cytotoxic drugs, 48
Cytoxan, 49
- darbepoetin alfa (Aranesp), 50
depression, 87, 102, 103
diabetes, 82
diazepam (Valium), 114
DIEP (free flap), 132
diet, 82–83. *See also* nutrition
 calcium in, 83, 116–117
 CAM and, 76, 77, 79
 and cancer risk / prevention, 10, 11, 12, 14, 137
 with chemotherapy, 58
 fats in, 82, 137
 flax in, 83
 guidelines during cancer treatment, 83
 for heart health, 117–118
 magnesium in, 117
 soy in, 83
 vitamin D in, 83, 117
diagnosis, 17, 20, 26, 47, 64, 96, 130, 131, 132, 137
dietician, registered, 83
DNA
 changes related to breast cancer, 8, 128, 129
 tests / studies, 28, 45
docetaxel (Taxotere), 49, 133
doxorubicin (Adriamycin), 49, 56
drugs. *See also* chemotherapy; systemic therapy, 133

- anticancer, 12–13
for insomnia, 114
ductal carcinoma in situ (DCIS), 4, 27, 29, 33
- Eastern Cooperative Oncology Group (ECOG), 70
- electrical impedance imaging, 18
- emotions surrounding breast cancer, 102–104
managing, 115
research on, 136
- endocrine therapy, 28, 30, 44, 46–48, 52, 96
bisphosphonates and, 52, 135
oral, 46
research, 130
- endometrial cancer, 10, 12, 47, 130
- epoetin alfa (Procrit, Epo), 50
- epothilones, 133
- estrogen
levels as related to cancer, 46, 48
replacement therapy, 112
research on, 131
and risk, 8, 12
supplemental, 9, 112
tests for, 28
vaginal, 9, 116
- exemestane (Aromasin), 13, 28, 46
- exercise
in CAM therapies, 76, 79
for menopausal side effects, 112
during physical rehabilitation, 86–87
as protective factor, 12, 14, 82, 117, 137
and relaxation, 115
- external beam radiation, 40, 41
- Family and Medical Leave Act (FMLA), 123
- family history, as risk factor, 10, 131
- family issues surrounding cancer, 104–106
- farnesyl transferase inhibitors, 135
- fatigue, 56, 86, 87, 93, 106, 136. *See also* side effects
- fear / anxiety, 102, 104, 107, 114
- fenretinide, 130
- Fertile Hope, 65
- fertility issues, 65
- fibroadenomas, 9
- filgrastim (Neupogen), 50, 57
- fine needle aspirate (FNA), 17
- 5-fluoro-uracil (5-FU), 49
- fluorescence in situ hybridization (FISH) testing, 51
- fluoxetine (Prozac), 113
- follow-up care, 92
- Food and Drug Administration (FDA), approvals, 18, 47, 72, 117, 128
- Fred Hutchinson Cancer Research Center, 9
- friends. *See* support groups
- Fulvestrant (faslodex), 47–48
- gabapentine (Neurontin), 113
- gemcitabine (Gemzar), 49
- genes
analysis, 131
cancer-related, 28, 128, 129
susceptibility (BRCA1 and BRCA2), 10
- genetic(s)
research, 129
as risk factor, 8
testing, 11
- genomic profiling, 131
- Gilda's Club, 79
- grief surrounding cancer, 102–103
- gynecologic exams, 92
- hair loss, 105, 106. *See also* alopecia
- health care wishes (durable power of attorney, directives, wills), 124–125
- Health Insurance Portability and Accountability Act (HIPAA), 122
- heart attack risk, 47
- heart disease, 82, 117, 118
- heat therapy (moxibustion), 79
- Herceptin, 51, 134
- hereditary. *See* genetic(s)
- HER-2, 28, 51, 128, 134
- herbal medicines / herbs, 77, 78, 79
- homeopathy, 77
- hormone-receptors, 45, 131
tests, 28
- hormone replacement therapy (HRT), 9
- hormones
postmenopausal, 9
role of, 8
- hormone therapy, 128. *See also* endocrine therapy
- hospice care / services, 98–99
- hot flashes and night sweats, 112–113, 136
- human genome, 128
- hydrotherapy, 78
- hyperplasia, 9, 33
- hysterectomy, 9
- ibandronate (Bondronat, Boniva), 52, 117
- IBIS II Trial, 13, 130
- IGFR, 136
- imaging techniques, 18, 29
- immune system, 76, 87
- immunohistochemical (IHC) testing, 51
- implantable venous access devices, 53, 54
- implants
silicone, 35
tissue, 35, 37
- infection, 87, 89, 90
- infiltrating ductal cancer, 26
- infiltrating lobular cancer, 26
- informed consent, 72
- insomnia, menopausal, 113–114
- Institutional Review Board (IRB), 72
- insurance issues and coverage, 21, 30, 36, 37, 57, 59, 60, 61, 92
in clinical trials, 75
filing a claim, 122–123
of physical therapy, 90
PPOs, POS, and HMOs, 121
for terminal illness, 98–99
- intraductal carcinoma, 27
- intravenously, administration of drugs, 52
- investigational new drug (IND), 72
- isoflavones, 83
- Ixabepilone, 133
- ki67 measurement, 28
- Kytril, 58
- lactation, as preventive, 8
- lapatinib (Tykerb), 134
- Last Acts, 99
- lat flap, 37
- legal issues and assistance, 123–125
- letrozole (Femara), 13, 28, 46
- lifestyle
in CAM therapies, 76
healthy, 93
menopausal changes in, 112–113
to prevent recurrence, 137
role of, in breast cancer, 4, 11, 129
- liposomal doxorubicin (Doxil), 49
- lobular carcinoma in situ (LCIS), 9, 33
- lobules, 26
- lorazepam (Ativan), 58
- lumpectomy, 29, 32, 40, 41, 122, 132
- lung cancer, 51, 135
- lupus, 33
- lymphatic system, 26, 45
- lymphedema, 52, 88–90
- lymph nodes, 26, 33, 40, 44, 52
evaluation, 33–34, 131
mapping, 132
removal, 88
- lymphoma, 33
- magnetic resonance imaging (MRI), 18, 29, 92
- malignant, 26, 128
- Mammaprint 70-gene Profiling Assay, 131
- mammogram and mammography screening, 4, 9, 17, 18, 26, 29, 33, 92, 130, 131
in Washington state, 122
- manipulation, spinal, 78
- MAP-3 (EXCEL) Trial, 13, 130
- marker. *See* tumor, markers
- massage / massage therapy, 76, 77–78, 79, 90
- mastectomy, 32, 33, 34, 132
and body image, 106
bras, 58–60
modified radical, 32
prophylactic, 13–14
and prosthesis, 58
and reconstruction, 35, 37
- Medicare, Medicaid, and Medigap eligibility and coverage, 37, 59, 61, 98, 120, 121–122, 123
- meditation, 113, 115
- medroxy progesterone (Megace), 113
- menopause, 9
chemotherapy and early, 65, 112
and differences between
premenopausal and postmenopausal women, 46, 47, 48, 130, 137
insomnia, 113–114
and sexuality, 115
side effects / symptoms, 112, 116, 136
symptoms of, 106, 107, 114–115
- menstrual
changes during treatment, 58
history, as risk factor, 8
- metabolism, 131
- metastasis, 27, 44, 47, 52, 98–99, 135. *See also* Breast cancer, metastatic
- methotrexate, 49, 134
- metronomic dosing, 49
- microcalcifications, 33
- mind–body strategies, 76
- MRI (magnetic resonance imaging), 130–131
- mucositis, 57
- music therapy / therapists, 78, 79
- mutations, 9, 10, 11, 28, 128, 129
- National Breast Cancer Coalition (NBCC), 141
- National Cancer Institute (NCI), 69
Office of Cancer Survivorship, 136
- National Institutes of Health (NIH)
clinical trials database, 133
Consensus Conference on the

- Treatment of Early Stage Breast Cancer, 32
- National Surgical Breast and Bowel Project (NSABSP) STAR Trial, 13, 41, 70, 130, 133
- natural childbirth, 78
- naturopathic physicians (ND), 78, 79
- neoadjuvant therapy, 30, 44–45
- neutropenia, 57
- neutrophils, 50, 57
- North Central Cancer Treatment Group (NCCTG), 70
- Northwest Justice Project, 124; Appendix B
- Northwest Women's Law Center, 124
- Nottingham scale, 28
- NSABP (National Surgical Breast and Bowel Project) Breast Cancer Prevention Trial, 12
- STAR (Study of Tamoxifen and Raloxifene) Trial, 13, 41, 70, 130
- nuclear power, as risk factor, 8
- nutrition, 22, 77, 78, 87. *See also* diet tips, 82–83
- nutritional / diet supplements, 58, 77, 83, 118
- obesity / overweight, as risk factor, 10, 82, 118
- occupational therapists, 90
- oncogenes, 28
- studies (HER-2), 45, 128–129
- oncologists / oncology, 9, 65
- advice on estrogen support, 112
- and clinical trials, 69, 133
- Oncotype Dx21 gene Recurrence Score Assay, 131
- oophorectomy, 48
- oral contraceptives. *See* birth control pills
- Organizations and Resources (Appendix B), 164
- Exercise, Alternative Medicine and Nontraditional Therapies, 169
- Financial, Legal and Insurance Resources, 170
- Hospice and Palliative Care, 172
- Hotlines, 178
- Medical Research and Resources, 173
- for Specific Populations, 174
- Support groups, 179
- Transportation, 188
- oriental medicine, 76, 78–79
- osteoporosis, 47, 52, 83
- drugs, 135
- preventing, 116–117
- ovarian cancer, 10
- ovaries, 46, 48. *See also* endocrine therapy
- p53 tests, 28
- paclitaxel (Taxol), 49, 133
- palliative care, 98–99
- palpate, 16
- pamidronate (Aredia), 52, 135
- pap smears, 92
- parathyroid hormone, 117
- partial breast radiation, 41, 132–133
- pathologist, 8, 9
- patient safety, 72
- peer support, 66
- pegfilgrastim (Neulasta), 50, 57
- pemetrexed (Alimta), 133–134
- personal history, as risk factor, 10
- PET scans, 131
- physical activity. *See* exercise
- physical therapy / therapists, 88, 89. *See also* physical rehabilitation
- physical rehabilitation, 86–90
- physical therapeutics, 78. *See also* exercise
- phytoestrogens, 83, 113
- placebo, 72
- platelets, 49
- ploidy, 45
- poroxitine (Paxil), 113
- ports. *See* implantable venous access devices, 53
- postmenopausal hormones, 28
- prayer, 97, 113, 115
- pregnancy, as risk factor, 8
- as treatment consideration, 33
- prevention, breast cancer, 11, 47, 128, 129, 130, 137
- primary systemic therapy, 30
- prochlorperazine (Compazine), 58
- progesterone
- levels and cancer, 46
- as risk factor, 9
- tests for, 28
- prostheses
- and bras, 58–61
- cranial, 57
- proteins, 28, 128
- mTOR, 135
- publications, 192 (Appendix C)
- Qi Gong, 86–87
- quality of life, 136
- Race for the Cure®, 140–141
- radiation
- and breastfeeding, 65
- exposure, 9
- ionizing, 8
- partial breast, 41, 132–133
- pneumonitis, 41
- port, 40
- after recurrence, 96
- and reproductive system, 65
- skin changes during, 87–88
- radiation therapy, 29, 33, 35, 40–41, 44, 45, 76
- exercise during, 86
- and lymphedema, 88–90
- side effects of, 41
- skin changes during, 87
- radiation oncologists, 30
- radioactive isotope marker substance, 34
- radiologic imaging, 92
- RAD001 (everolimus), 135
- ralcitonin, 117
- raloxifene (Evista), 13, 117, 130
- red blood cells, 49
- research, 128. *See also* clinical trials; genetic(s)
- retilafaxine (Effexor), 113
- retinoids, 130
- risedronate (Actonel), 117
- risk / risk factors, 8–11, 130
- reducing / preventing, 11–14, 82, 86
- research on, 130, 136
- in surgical procedures, 37
- Robert Wood Johnson Foundation, 98
- scintimammography, 18
- scleroderma, 33
- screening mammography. *See* mammogram, screening
- second opinion, 30
- selective estrogen-receptor downregulators (SERDs), 47
- selective estrogen-receptor modulators (SERMs), 13, 47
- selective serotonin reuptake inhibitors (SSRI), 113
- sentinel lymph node biopsy, 34
- sentimental lymph node mapping, 132
- serotonin receptor antagonists, 58
- sexuality and sexual intimacy during cancer, 106–107
- SHIBA (Statewide Health Insurance Benefits Advisors), 121–122
- side effects, 106, 132
- fatigue, 56, 86, 87, 93, 136
- hair loss (alopecia), 56
- of menopause, 112
- menstrual changes, 58
- mucositis, 57
- nausea, 58, 77
- neutropenia, 57
- in young women, 66
- silicone in prostheses, 58, 59
- Sister Study, 129
- skin changes / scarring, 87–88
- sleep, importance of, 22
- Social Security Administration, 120, 123
- Southwest Oncology Group (SWOG), 13, 49, 52, 70, 130, 135
- S-phase measurements, 28, 45
- spirituality and prayer, 97, 113, 115
- staging (stages), 26–28, 65
- STAR (Study of Tamoxifen and Raloxifene), 13, 41, 70, 130
- stem cell transplants, 50
- stereotactic breast biopsy, 17
- studies, single- and double-blind, 71
- sunitinib malate (Sutent), 136
- support groups, 93, 98, 105, 107, 108–109, 115; Appendix B, Appendix C
- Suppression of Ovarian Function Trial (SOFT), 48
- surgery / surgeon, 44, 76, 132. *See also* breast reconstruction; lumpectomy; mastectomy
- axillary lymph node evaluation, 35–36
- and breastfeeding, 65
- at early stages, 29, 40
- and questions to ask surgeon, 34
- reconstruction, 35, 37
- and reproductive system, 64
- skin changes after, 87
- systemic therapy, 29–30, 44, 45, 46, 133–136
- Tai Chi, 87, 113
- taxanes, 49, 133
- Taxol, 49, 52, 135
- tamoxifen (Nolvadex), 12, 28, 29, 46, 47, 117, 130
- Tamoxifen and Exemestane Trial (TEST), 48
- targeted therapy, 44, 134, 135–136
- taxane drugs, 49
- temazepam (Restoril), 114
- therapy. *See also* systemic therapy; treatment adjuvant, 44–45
- “local,” 44
- neoadjuvant, 30, 44–45
- thermography, 18
- thymidine, 131

- tipifarnib (Zarnestra), 135
- tissue density, as risk factor, 9
- tissue transplants, 35–36
- toremifene (Fareston), 47
- toxicity. *See* side effects
- traditional Chinese medicine (TCM), 77, 79
- TRAM flap*, 37, 132
- trastuzumab (Herceptin), 51, 128, 134
- treatment, cancer, 137
 - incorporating CAM, 76–80
 - conventional, 76
 - decisions, 23
 - evaluation of, 68
 - metastatic (Stage IV), 45–46
 - options, 29–30, 44
 - post-, 109
 - at recurrence, 96
 - of young women with breast cancer, 65
- triazolam (Halcion), 114
- tumor*
 - grade, 28
 - markers, 28–29, 92
 - size, 26, 45, 131
- tumor suppressor genes, 28, 129
- Tykerb, 134

- ultrasound, 17, 18, 29
- U.S. Department of Labor, Wage and Hour Division, 123
- U.S. Food and Drug Administration (FDA), 35
- uterine cancer, 8, 130. *See also* endometrial cancer

- vaccines, cancer, 136
- vaginal dryness and lubricants, 116, 136
- vascular endothelial growth factor (VEGF), 51

- vinorelbine (Navelbine), 49
- volunteer activities, 140–141

- Washington State
 - Basic Health Plan, 120
 - Department of Health (licensure), 78, 79, 80
 - Department of Social and Health Services, 123
 - health insurance, 121
 - Insurance Commissioner's office, 121, 123
 - mandatory breast cancer-related health benefits, 122
 - Medical Assistance Administration, 120
 - public assistance, 120
 - SHIBA, 121, 122
- Western Washington Breast Cancer Treatment Centers, 144 (Appendix A)
- white blood cells (*T-cells*), 57. *See also* neutrophils
- Women's Health Initiative (WHI) trial, 9
- Women's Intervention Nutrition Study (WINS), 137
- written record, 21

- X-ray, and radiation therapy, 40

- Y-ME, 61, 121
- yoga, 86, 113, 115

- Zofran, 58
- zoledronic acid (Zometa), 52, 135
- zolpidem (Ambien), 114
- Zometa, 135